CH703437A2 - Use of an active mixture of essential oils and volatile synthetic molecules as pulmonary tuberculosis therapy by inhalation of the mixture which is essence of clove, eugenol, thyme, synthetic thymol and methyl jasmonate - Google Patents
Use of an active mixture of essential oils and volatile synthetic molecules as pulmonary tuberculosis therapy by inhalation of the mixture which is essence of clove, eugenol, thyme, synthetic thymol and methyl jasmonate Download PDFInfo
- Publication number
- CH703437A2 CH703437A2 CH01072/10A CH10722010A CH703437A2 CH 703437 A2 CH703437 A2 CH 703437A2 CH 01072/10 A CH01072/10 A CH 01072/10A CH 10722010 A CH10722010 A CH 10722010A CH 703437 A2 CH703437 A2 CH 703437A2
- Authority
- CH
- Switzerland
- Prior art keywords
- mixture
- essential oils
- active
- synthetic molecules
- volatile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Introduction et état de science actuelIntroduction and current state of science
[0001] La tuberculose est une maladie contagieuse touchant principalement le poumon, mais peut aussi affecter d’autres parties du corps, comme la colonne vertébrale, le cerveau et les reins. L’agent pathogène, le Mycobacterium tuberculosis est transmis par des gouttelettes de toux et d’expectorations. Tuberculosis is a contagious disease affecting mainly the lung, but can also affect other parts of the body, such as the spine, brain and kidneys. The pathogen, Mycobacterium tuberculosis, is transmitted by droplets of cough and sputum.
[0002] La tuberculose affecte de plus en plus des personnes surtout dans les pays en voie de développement d’où se trouve un grand nombre de patients atteints du VIH/SIDA avec un mauvais accès aux soins de santé. [0002] Tuberculosis is affecting more and more people, especially in developing countries where there is a large number of HIV / AIDS patients with poor access to health care.
[0003] Le Mycobacterium tuberculosis possède une enveloppe lipidique et développe de plus en plus une résistance aux agents chimiques des traitements usuels et son éradication est longue. Une amélioration considérable du traitement de la tuberculose par un mélange des huiles essentielles qui est respiré par le patient est l’objet de la demande du brevet décrite en suite. [0003] Mycobacterium tuberculosis has a lipid envelope and is developing more and more resistance to the chemical agents of the usual treatments and its eradication is long. A considerable improvement in the treatment of tuberculosis by a mixture of essential oils which is breathed by the patient is the subject of the patent application described below.
L’InventionThe Invention
[0004] Nous avons trouvé que le mélange de trois produits volatils ayant une action synergétique et est capable de tuer le Mycobacterium tuberculosis quand celui est en contact avec les vapeurs de ce mélange. We found that the mixture of three volatile products having a synergistic action and is able to kill Mycobacterium tuberculosis when it is in contact with the vapors of this mixture.
[0005] Ce mélange consiste en ces trois substances: <tb>1.<sep>Huile essentielle de girofle obtenu par stillation des feuilles ou boutons (clous de girofle) de l’arbre Eugenio Caryophyllata. <tb>2.<sep>Huile essentielle du thym rouge obtenu par distillation de la plante entière Thymus Vulgaris. <tb>3.<sep>Jasmonate de méthyle, une molécule présente naturellement dans le thé vert.This mixture consists of these three substances: <tb> 1. <sep> Essential oil of clove obtained by stillation of the leaves or buds (cloves) of the Eugenio Caryophyllata tree. <tb> 2. <sep> Essential oil of red thyme obtained by distillation of the whole plant Thymus Vulgaris. <tb> 3. <sep> Methyl Jasmonate, a molecule found naturally in green tea.
[0006] La substance active dans l’essence de girofle est l’eugénol qui peut être isolé par distillation de l’essence girofle brute. La substance active dans l’essence de thym est le thymol qui est accessible aussi par synthèse chimique. Le Jasmonate de méthyle est présente dans le thé vert, mais pour les parfums et arômes on utilise exclusivement la molécule de synthèse chimique connue en commerce sous le nom de «Hedione» de la maison Firmenich à Genève, Suisse. The active substance in clove oil is eugenol which can be isolated by distillation of crude clove oil. The active substance in the essence of thyme is thymol which is also accessible by chemical synthesis. Methyl Jasmonate is present in green tea, but for perfumes and flavors only the chemical synthesis molecule known commercially under the name "Hedione" from Firmenich in Geneva, Switzerland, is used.
[0007] Théoriquement on pourrait utiliser ces substances pures mais nous avons constaté que leur action dans l’ensemble de l’huile essentielle naturelle qui contient en plus une multitude d’autres molécules actives est nettement supérieure et plus agréablement à utiliser. En plus de l’action bactéricide des mélanges actifs cités on peut ajouter des huiles essentielles ou molécules ayant une action anti-inflammatoire. Theoretically we could use these pure substances but we found that their action in the whole of the natural essential oil that contains in addition a multitude of other active molecules is significantly superior and more enjoyable to use. In addition to the bactericidal action of the active mixtures mentioned, it is possible to add essential oils or molecules having an anti-inflammatory action.
[0008] Le Mycobacterium tuberculosis provoque par son action qui inclut entre autres l’enzyme lipoxygenase une inflammation du tissu environnant. De ce fait des substances volatiles ayant une action antioxydant (capteurs de radicaux libres et des peroxydes) qui diminuent l’inflammation ont un effet bénéfique quand elles sont inhalées ensemble avec le mélange actif. L’essence de sauge, de la bergamote, du citron, du vétiver, de la camomille, la vanilline et d’autres a un effet anti-inflammatoire. [0008] Mycobacterium tuberculosis causes by its action which includes among others the lipoxygenase enzyme an inflammation of the surrounding tissue. As a result, volatile substances having an antioxidant action (free radical scavengers and peroxides) which decrease inflammation have a beneficial effect when they are inhaled together with the active mixture. The essence of sage, bergamot, lemon, vetiver, chamomile, vanillin and others has an anti-inflammatory effect.
Exemple 1:Example 1
[0009] Mélange active No 1: <tb>Essence de girofle rectifié<sep>50,0 % <tb>Essence de thym<sep>20,0 <tb>Hedione<sep>30,0Active mixture No 1: <tb> Rectified clove oil <sep> 50.0% <tb> Essence of thyme <sep> 20.0 <Tb> Hedione <September> 30.0
[0010] Ce mélange est testé selon la méthode de l’inhibition de croissance. Germe de test: Mycobacterium tuberculosis ATCC 25177 This mixture is tested according to the growth inhibition method. Test germ: Mycobacterium tuberculosis ATCC 25177
[0011] Milieu de culture: Gélose Lôwenstein-Jensen (voir Murray et al. Manual of Clinical Microbiology, 7. Ed. ASM press). La gélose de culture est dans une éprouvette avec la surface en pente. Les Mycobactéries sont inoculés à la surface de la gélose. Ensuite on a coulé 100 microlitres du mélange active 1 sur la surface inoculé. Les éprouvettes sont ensuite incubées à 37 °C pour une période de 6 semaines. Après la croissance du Mycobacterium a été comparé avec un contrôle qui n’avait pas reçu le mélange actif. Nous avons observé une inhibition de croissance complète sur la surface touchée directement par le mélange active 1 et une croissance fortement diminuée à la surface touchée seulement par les vapeurs de ce mélange. Culture medium: Löwenstein-Jensen agar (see Murray et al., Manual of Clinical Microbiology, 7. Ed ASM press). The culture agar is in a test tube with the sloping surface. Mycobacteria are inoculated on the surface of the agar. Then 100 microliters of the active mixture was poured onto the inoculated surface. The specimens are then incubated at 37 ° C for a period of 6 weeks. After the growth of Mycobacterium was compared with a control that had not received the active mixture. We observed complete growth inhibition on the surface directly affected by the active mixture 1 and greatly reduced growth on the surface affected only by the vapors of this mixture.
Exemple 2:Example 2
[0012] En utilisant les mêmes germes de test inoculés sur le même milieu de culture comme décrit dans l’exemple 1 nous avons vaporisé le mélange suivant à la surface de culture Préalablement inoculé: Using the same test seeds inoculated on the same culture medium as described in Example 1 we sprayed the following mixture on the culture surface Previously inoculated:
[0013] Mélange active 2: <tb>Essence de girofle rectifié<sep>40,0 % <tb>Essence de thym<sep>20,0 <tb>Thymol synthétique<sep>10,0 <tb>Hedione<sep>30,0Active mixture 2: <tb> Rectified clove oil <sep> 40.0% <tb> Essence of thyme <sep> 20.0 <tb> Synthetic Thymol <sep> 10.0 <Tb> Hedione <September> 30.0
[0014] La vaporisation a été effectuée avec un appareil Aeroneb ProX-nebulisateur (fabricant Aerogen Ltd., Galway, Irlande) The vaporization was carried out with a device Aeroneb ProX-fogger (manufacturer Aerogen Ltd., Galway, Ireland)
[0015] Pour le test pratique, une croissance de culture de Mycobacterium tuberculosis d’une semaine a été exposée pendant 5 minutes aux microgouttelettes et vapeurs du mélange actif. Pour obtenir une meilleure vaporisation chaque mélange actif à été dilué comme suit: 20% mélange active dans éthanol 30% sol. aqueuse. Mélange active 1 et 2 ont été testé en parallèle. Ensuite les éprouvettes sont incubées à 37°C pendant 24 heures. Cette procédure est répétée pendant 10 jours consécutifs. For the practical test, a culture growth of Mycobacterium tuberculosis of one week was exposed for 5 minutes to microdroplets and vapors of the active mixture. To obtain a better vaporization, each active mixture was diluted as follows: 20% active mixture in ethanol 30% sol. aqueous. Active mixture 1 and 2 were tested in parallel. Then the specimens are incubated at 37 ° C for 24 hours. This procedure is repeated for 10 consecutive days.
[0016] A la fin de cette période la croissance des bactéries était fortement diminuée en comparaison visuelle avec le contrôle non traité. At the end of this period the growth of bacteria was greatly reduced in visual comparison with the untreated control.
[0017] Il est connu que l’éthanol seul n’a aucune action sur Mycobacterium tuberculosis. De ce fait l’action inhibitrice est due seulement aux mélanges actifs. It is known that ethanol alone has no action on Mycobacterium tuberculosis. As a result, the inhibitory action is due only to the active mixtures.
Exemple 3:Example 3
[0018] Le même test décrit dans l’exemple 2 a été répété en utilisant un spray aérosol avec propulseur liquéfié à la place du nebulisateur. The same test described in Example 2 was repeated using an aerosol spray with liquefied propellant instead of the nebulizer.
[0019] Formule aérosol: <tb>2,0 %<sep>mélange active 1 ou 2 <tb>98,0 %<sep>propulseur propane/butane 2,5 barAerosol formula: <tb> 2.0% <sep> active mixture 1 or 2 <tb> 98.0% <sep> propane / butane propellant 2.5 bar
Application:Application:
[0020] 4 fois 1 seconde de spray ont été dirigé vers la surface gélose préalablement inoculée avec Mycobacterium tuberculosis et incubée pendant 1 semaine à 37 °C. Après l’éprouvette de test est de nouveau incubé à 37 °C. Chaque jour ce même traitement est appliqué sur la surface de gélose pour une période de 7 jours. 4 times 1 second of spray were directed to the agar surface previously inoculated with Mycobacterium tuberculosis and incubated for 1 week at 37 ° C. After the test specimen is incubated again at 37 ° C. Each day this same treatment is applied to the agar surface for a period of 7 days.
Résultat:Result:
[0021] Nous avons observé une inhibition de croissance complète du Mycobacterium tuberculosis après 7 jours de traitement déjà. Mélange active 1 et 2 ont montré les mêmes résultats. Pour vérifier l’effet létal de ces formules nous avons subcultivé des Mycobactéries de la surface gélose traitée sur le même milieu de culture Löwenstein-Jensen frais et incubé pendant 6 semaines à 37 °C pour vérifier s’il y a présence des cellules vivantes. Aucune croissance n’a été observée sur les éprouvettes traitées. Par contre la subculture du contrôle sans traitement a montré une forte croissance après 2 semaines d’incubation déjà. We observed a complete growth inhibition of Mycobacterium tuberculosis after 7 days of treatment already. Active mix 1 and 2 showed the same results. To verify the lethal effect of these formulas we subcultivated Mycobacteria from the treated agar surface on the same fresh Löwenstein-Jensen culture medium and incubated for 6 weeks at 37 ° C to check for presence of living cells. No growth was observed on the treated specimens. On the other hand, the subculture of the control without treatment showed a strong growth after 2 weeks of incubation already.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH01072/10A CH703437A2 (en) | 2010-07-01 | 2010-07-01 | Use of an active mixture of essential oils and volatile synthetic molecules as pulmonary tuberculosis therapy by inhalation of the mixture which is essence of clove, eugenol, thyme, synthetic thymol and methyl jasmonate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH01072/10A CH703437A2 (en) | 2010-07-01 | 2010-07-01 | Use of an active mixture of essential oils and volatile synthetic molecules as pulmonary tuberculosis therapy by inhalation of the mixture which is essence of clove, eugenol, thyme, synthetic thymol and methyl jasmonate |
Publications (1)
Publication Number | Publication Date |
---|---|
CH703437A2 true CH703437A2 (en) | 2012-01-13 |
Family
ID=45446393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH01072/10A CH703437A2 (en) | 2010-07-01 | 2010-07-01 | Use of an active mixture of essential oils and volatile synthetic molecules as pulmonary tuberculosis therapy by inhalation of the mixture which is essence of clove, eugenol, thyme, synthetic thymol and methyl jasmonate |
Country Status (1)
Country | Link |
---|---|
CH (1) | CH703437A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111867602A (en) * | 2018-03-26 | 2020-10-30 | 丽年控股有限公司 | Method for delivering amphiphilic biologically active substances targeted to the respiratory tract |
-
2010
- 2010-07-01 CH CH01072/10A patent/CH703437A2/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111867602A (en) * | 2018-03-26 | 2020-10-30 | 丽年控股有限公司 | Method for delivering amphiphilic biologically active substances targeted to the respiratory tract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prudent et al. | Analysis of the essential oil of wild oregano from Martinique (Coleus aromaticus Benth.)—evaluation of its bacteriostatic and fungistatic properties | |
Mercier et al. | The essential oil of turpentine and its major volatile fraction (α-and β-pinenes): A review | |
KR100285781B1 (en) | Essential oil composition with antibacterial and antifungal action | |
Poaty et al. | Composition, antimicrobial and antioxidant activities of seven essential oils from the North American boreal forest | |
Abbas et al. | Nematicidal activity of spices against Meloidogyne javanica (Treub) Chitwood | |
CN112335691A (en) | Antibacterial and acarid-removing composite essential oil | |
CN109394597B (en) | Special antibacterial natural deodorant extracted from cypress for pet and preparation method thereof | |
KR102292707B1 (en) | Antiviral composition comprising natural substance-derived substance and acidic hypochlorous acid | |
CH703437A2 (en) | Use of an active mixture of essential oils and volatile synthetic molecules as pulmonary tuberculosis therapy by inhalation of the mixture which is essence of clove, eugenol, thyme, synthetic thymol and methyl jasmonate | |
Hung et al. | In vitro antimicrobial activity of hydrosol from Litsea cubeba (Lour.) Pers. against Helicobacter pylori and Candida albicans | |
CN105708763B (en) | A kind of floral water containing Folium Artemisiae Argyi extract and preparation method thereof | |
CN104491121B (en) | It is a kind of to be used to treat antibacterial Essence of breathing problem and preparation method thereof | |
FR2748204A1 (en) | Antiseptic use of distilled Melaleuca essential oil | |
Nyegue et al. | Chemical composition of essential oils of Eugenia caryophylla and Mentha sp cf piperita and their in vitro antifungal activities on six human pathogenic fungi | |
Peterson | The essential oils of Indonesia | |
Soulimani et al. | Toxicological aspects and pharmaco-therapeutic properties of linalool, a natural terpene derivative of essential oils: Literature studies | |
KR102200405B1 (en) | Spray liquid compositions for antibacterial and deodorization and articles thereof | |
Sen | Esters, terpenes and flavours: Make the mood cheers by three musketeers | |
Ouryemchi et al. | GC-MS characterization, antioxidant, antimicrobial and insecticidal potential of Moroccan Cuminum cyminum L. essential oil | |
RU2093171C1 (en) | Medicinal agent | |
Bibi et al. | Biological Importance of Essential Oils from the Family Rutaceae | |
Baker et al. | Geranium oil profile | |
Adib | LEMONGRASS EXTRACT (Cymbopogon Nardus. L) AS PLANT INSECTICIDE AMERICAN COCKROACHES | |
Ahmad et al. | Chemical conversions of essential oil components and their properties–A review | |
Kılıç et al. | Liquidambar orientalis Miller |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AZW | Rejection (application) |